Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
Zevra Therapeutics has successfully submitted a U.S. patent for its drug MIPLYFFA to the FDA's Orange Book, strengthening its intellectual property protection with exclusivity extending to 2041. This development solidifies Zevra's position in treating Niemann-Pick disease type C and enhances the long-term commercial value of MIPLYFFA. A patent term…